14th March 2018
SIBO: Small Intestinal Bacterial OvergrowthTreatments & Therapies
What is SIBO?
Small intestinal bacterial overgrowth, or SIBO, is characterized as a disorder of excessive bacteria in the small intestine. Our gastrointestinal tract hosts over 100 trillion bacteria, where the vast majority being housed in the large bowel. A healthy small bowel has about 10,000 organisms/mL whereas in the bacterial population of a patient with SIBO has over 1-10 million organisms/mL (1). The type of microbial flora in the small intestine also plays an important role in the manifestation of signs and symptoms of an overgrowth. An example of this imbalance is when there is a predominance of bacteria that destroys bile salts fat malabsorption occurs, or if gram negative coliforms, such as Klebsiella overgrow it can produce a toxin that destroys the cellular wall of the gut (2). As populations of dysfunctional bacterial increase in the small intestine it disturbs gut immune function, leading to a reduced resistance to infection, and further inflammation of the gut wall.
Symptoms:Common manifestation of SIBO are nonspecific GI issues which include:
- Bloating and flatulence
- Abdominal distension and/or pain
- Chronic diarrhea
- Chronic constipation
- Fatigue and malaise
- Brain fog
Later symptoms or complications of untreated SIBO may include:
- Fat malabsorption
- Nutritional deficiencies, particularly fat soluble vitamins
- Weight loss
- Protein deficiency
Causes and Risk factors:
There are many causes that can lead to SIBO, but it is based on the foundation that anything that changes the normal balance of the GI system may be a contributing factor. The most common risk factors include:
- Low stomach acid
- Impaired gut motility. This can be due to a primary disorder affecting the nervous tissue of the intestinal tract, or secondary to long-standing diabetes, connective tissue disorders, prior viral infections, or poor blood circulation.
- Structural abnormalities either due to congenital defects, disease complications, or surgery. Compromised immune function. Patients who are immunocompromised are prone to SIBO IBS
- Metabolic disorders such as poorly controlled diabetes
- Inflammatory bowel diseases such as Crohn’s or Ulcerative Colitis Chronic diarrhea or constipation
Clinical diagnosis of SIBO can be challenging and usually requires a detailed history taken by a physician and further testing. Here at INMC we offer a SIBO lactulose breath test. This test is performed at home, and involves a 24 hour preparation period. This is followed by ingestion of lactulose which feeds bacteria in the small intestine, and then produces certain gases. These gases can be detected in the breath which is collected and analyzed in our lab. The variability of the types and amounts of gases help aide in the diagnosis of SIBO.
To treat SIBO I follow the four R guideline:
- Remove for pathologic bacteria to thrive. This is normally done with diet and antibiotictherapy.
- Replace the nutrients that are required for optimal digestion. This may include nutritional vitamins and supplements, but also digestive aide’s such as betaine hydrochloric acid and digestive enzymes.
- Repairing the gut mucosa is next. This is particularly important with long standing SIBO. After a while the pathogenic bacteria eats away at the gut lining and needs repair over time.
- Reinoculate with the right bacteria is the last step. Many practitioners do a combination of probiotics with dietary regimens to implement this, and some implement fecal transplants.
Resources1. Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. 1999;94:1327–13312. Saltzman JR, Kowdley KV, Pedrosa MC, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology. 1994;106:615–6233. Riordan SM, McIver CJ, Wakefield D, et al. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. Am J Gastroenterol. 2001;96:494–500.